Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2004. The report primarily discloses changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADSs), rather than providing comprehensive financial results.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions involving directors and employee trusts.
Material Changes
Material changes reported in this filing relate to equity holdings:
- Employee Trust Transactions: On February 18, 2004, the GlaxoSmithKline Employee Trust sold 1,133 Ordinary Shares at £11.0026 and transferred 2,691 Ordinary Shares to participants in the SmithKline Beecham Mid-Term Incentive Plan.
- Director Option Exercises: On February 19, 2004, Director Dr. J-P Garnier exercised options over 231,052 ADSs (117,259 under the 1989 Plan and 113,793 under the 1991 Plan) at a price of $14.5305 per ADS.
- Director Share Sales: Dr. Garnier sold 142,250 ADSs on February 19, 2004, at $43.1866 per ADS, principally to cover tax and costs associated with the option exercises.
- Net Position Change: Following these transactions, Dr. Garnier's total shareholding increased by 88,802 ADSs (a 78% increase) to a total of 203,167 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document serves solely to report specific insider trading activities and trust movements.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr. J-P Garnier (203,167) against subsequent filings.
- Confirm the exercise price ($14.5305) and sale price ($43.1866) used in the February 19, 2004 transactions.
- Review the status of the SmithKline Beecham Mid-Term Incentive Plan and the GSK Trust for further employee equity movements.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.